Press Releases
Hogan Lovells advises Gilead Sciences in long-acting HIV therapy collaboration agreement with Merck
17 March 2021
Senior AssociateWashington, D.C.
Email nadia.aksentijevich@hoganlovells.com
Phone +1 202 637 2454
Fax +1 202 637 5910
LanguagesEnglish, Serbian
Practice groupIntellectual Property, Media, and Technology
Nadia Aksentijevich advises companies looking to protect and optimize their IP portfolios by leveraging her experience in both patent prosecution and IP transactions to provide holistic advice.
Whether negotiating complex licensing and collaboration agreements, conducting diligence on IP components in mergers and acquisitions, or counseling clients in connection with their patent portfolio strategies, Nadia always keeps her client's business objectives top of mind.
With a background in biology and chemistry and research experience in infectious diseases at the National Institutes of Health, Nadia focuses on representing both public and private life science companies. She employs a creative, results-oriented approach to negotiating licensing and collaboration agreements, counseling on portfolio strategies and handling a wide range of operational agreements that are important to active life science companies, such as sponsored research agreements, materials transfer agreements, clinical trial agreements, supply agreements and co-promotion agreements. She also regularly advises clients across a variety of industries, including food technology, software, and media on patent strategy issues, including freedom-to-operate, landscape, and invalidity analyses, as well as on transactional matters. Nadia is a registered patent attorney.
Education
J.D., Boston College Law School, 2014
B.A., The University of Chicago, 2008
Bar admissions and qualifications
District of Columbia
New York
U.S. Patent and Trademark Office